Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Open-Label Single Arm Multicenter Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Doses of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH).

NCT07175038 is registered in ClinicalTrials.gov with AllRock Bio, Inc. as lead sponsor.

NCT NCT07175038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07175038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Open-Label Single Arm Multicenter Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Doses of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH).
Lead sponsor
AllRock Bio, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2025
Completion date
March 31, 2029
Enrollment
40 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah), pulmonary hypertension, interstitial lung disease